Aytu BioPharma, Inc.
Cash Flow Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-14.3M | $-13.6M | $-15.8M | $-17.1M | $-108.8M | $-58.3M | $-13.6M | $-27.1M |
| Depreciation & Amortization | $3.9M | $5.4M | $8.3M | $8.8M | $10.1M | $9.2M | $5.7M | $2.7M |
| Depreciation | $100.0K | $200.0K | $900.0K | $1.3M | $1.6M | $600.0K | $100.0K | — |
| Amortization | $2.5M | $3.7M | $3.7M | $4.8M | $5.8M | $6.0M | $4.5M | $2.1M |
| Stock-Based Compensation | $691.0K | $576.0K | $2.4M | $6.0M | $5.2M | $3.6M | $1.1M | $1.0M |
| Net Cash from Operating Activities | $3.3M | $-1.9M | $-1.4M | $-5.1M | $-28.8M | $-26.0M | $-28.4M | $-13.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $29.0K | $228.0K | $329.0K | — | $0 | $2.3M | $0 | $59.8K |
| Business Acquisitions | — | — | — | — | $0 | $15.5M | $5.9M | — |
| Net Cash from Investing Activities | $-29.0K | $-2.6M | $-329.0K | $-117.0K | $-3.2M | $-2.8M | $-5.7M | $-1.1M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-7.9M | $15.4M | $-1.3M | $8.9M | $1.5M | $30.3M | $71.1M | $19.1M |
| Net Change in Cash | $-4.6M | $10.9M | $-3.0M | $3.6M | $-30.5M | $1.6M | $37.0M | $4.2M |
| Free Cash Flow | $3.3M | $-2.2M | $-1.7M | — | $-28.8M | $-28.3M | $-28.4M | $-13.9M |